Removal of marketed unapproved drugs (MUDs), such as that with oral colchicine, is part of FDA's Unapproved Drugs Initiative (launched in 2006).
Removal of marketed unapproved drugs (MUDs), such as that with oral colchicine, is part of FDA's Unapproved Drugs Initiative (launched in 2006).
Single-ingredient oral colchicine products have been associated with adverse drug events (ADEs), including fatalities, and were never FDA approved.
MUDs are agents that have been marketed illegally, without approved New Drug Applications (NDAs) or Abbreviated NDAs (ANDAs). Most MUDs were older ingredients marketed in the United States prior to 1962, when the Kefauver-Harris Amendment to the Food, Drug and Cosmetic Act began requiring effectiveness, as well as safety data, in order to gain FDA approval. However, many of these ingredients were recently reintroduced, according to research presented during the Academy of Managed Care Pharmacy's 2010 Educational Conference in St. Louis.
Manolakis said, however, that not all unapproved drugs will require removal from the market; some serve important medical needs and should be submitted to FDA for review and approval to confirm that use is appropriate, and that the products: are documented to be safe and effective as marketed; include dosing recommendations and target patient populations that are grounded in scientific evidence; are labeled with necessary warnings; are manufactured according to modern, high-quality standards; and are named and labeled to avoid potential mix-ups and medication errors.
"As pharmacists working in different health-systems, we can help to reduce demand of these agents by encouraging their manufacturers to obtain FDA approval, require that only FDA-approved drugs be included on our formularies, and report ADEs," Manolakis said. "We also need to educate others that these agents are not safe and not FDA-approved."
These agents have been able to remain "used and available" because of misperceptions about grandfathering and approval laws, automatic inclusion of core drug groups on formularies, as well as providing blanket coverage of "all generics" and/or repackaged products. A serious implication of their use is that they are a safety risk to patients.
In the case of colchicine, one manufacturer has obtained FDA approval, therefore FDA has required that all other companies halt manufacturing and distribution of unapproved colchicine. Another serious implication of their use is that they are subject to fraud potential under Centers for Medicare and Medicaid Services (CMS) if used to treat Medicare Part D patients. Most unapproved drugs do not meet the definition of a covered Part D drug.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.